1. At a Glance – The Lab Equipment Company That Looks Profitable… Until You Read Depreciation
Tarsons Products is that student in class who looks like a topper from outside—clean lab coat, fancy pipette, global ambitions—but once you check the report card, you realize: marks toh theek hain, par rank kyun gir gaya?
Here’s the situation:
- Revenue is growing (₹107.89 Cr latest quarter)
- Margins are recovering (OPM ~29%)
- Demand is picking up (management literally said so)
- BUT… profit is struggling
- AND debt is quietly increasing
And then comes the villain of this Bollywood story:
Depreciation.
This company is spending aggressively on capex (₹800 Cr plan), building shiny new plants, expanding globally…
…but accounting profit is getting hammered because those assets are now sitting on the books like overweight gym subscriptions.
Even management is saying:
👉 “Ignore accounting PAT, look at cash profits.”
Translation:
“Boss, paper pe loss lag raha hai, par asli mein paisa aa raha hai.”
So what is Tarsons really?
- A future-ready labware giant?
- Or a capital-intensive science experiment investors didn’t sign up for?
Let’s dissect this like a proper lab report—minus the boring parts.
2. Introduction – From COVID Hero to Post-COVID Hangover
Tarsons was one of those companies that got a massive tailwind during COVID.
Everyone suddenly needed:
- PCR tubes
- Lab consumables
- Diagnostics equipment
And Tarsons was like:
“Beta, pipette bhi milega aur margin bhi.”
But here’s what management admitted:
👉 COVID created artificial demand spike for 2–3 years
👉 Industry over-expanded capacity
👉 Now pricing has crashed to “all-time low” levels
Meaning:
- Everyone built factories
- Now nobody has pricing power
Classic Indian market:
Jab demand hoti hai → sab invest karte hain
Jab supply aati hai → sab rote hain
Now Tarsons is stuck in this awkward phase:
- Demand returning ✔️
- Capacity ready ✔️
- Pricing weak ❌
So the question is simple:
👉 Will volume growth save them?
👉 Or will pricing pressure kill margins?
3. Business Model – WTF Do They Even Do?
Let’s simplify this.
Tarsons sells plastic labware products.
Think:
- Pipette tips
- Test tubes
- Cryovials
- Petri dishes
Basically everything scientists use before discovering something important (or blowing something up).
Revenue split:
- Consumables → 55%
- Reusables → 40%
- Instruments → 5%
Business model is:
👉 Sell cheap items in huge volumes
👉 Maintain repeat demand
👉 Build distribution network
And it works… because:
- Labs consume these daily
- Switching costs are high (especially for critical experiments)
In fact, management said:
👉 In cell culture products, switching cost is “much, much higher”
Meaning:
Once you enter a lab → you stay there like a Netflix subscription.
But here’s the twist:
👉 Old products become commoditized
👉 New products need R&D + trust
So Tarsons is
